Crown Laboratories Initiates Tender Offer To Buy Revance At $3.10/Share In Cash

(RTTNews) - Crown Laboratories, Inc., Thursday announced the commencement of a cash tender offer to acquire Revance Therapeutics, Inc., (RVNC) at a price of $3.10 per share.

The Revance board concluded that the offer is in the best interest of its shareholders. The company also said it has considered factors such as the changing dynamics of the aesthetic injectable market, and the potential risks related to its outstanding debt obligations.

The offer is set to expire at one minute after 11:59 p.m., ET on January 13, 2025, the privately held skincare company added.

Currently, Revance's stock is moving up 1.31 percent, to $3.08 on the Nasdaq.